The Three Contenders in 2026
The weight-loss injectable landscape in 2026 has three headliners. Zepbound (tirzepatide 15 mg), Eli Lilly's dual GIP/GLP-1 agonist, has been available since late 2023 and set new benchmarks for efficacy. Wegovy HD (semaglutide 7.2 mg), Novo Nordisk's higher-dose semaglutide, was approved in March 2026 and pushes semaglutide's weight loss closer to tirzepatide territory. And CagriSema, Novo Nordisk's fixed-dose combination of cagrilintide (amylin analog) plus semaglutide 2.4 mg, is currently under FDA review with a decision expected around October 2026.
Each drug uses a different mechanism. Each has strong clinical data. And only two of them are available right now. This comparison breaks down what matters so patients and prescribers can make practical decisions rather than waiting for a drug that is not yet on the market.
Mechanisms of Action Compared
The difference between these three drugs starts at the receptor level:
- Zepbound (tirzepatide) — A dual GIP + GLP-1 receptor agonist. It activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and GLP-1 receptors. The GIP component enhances fat metabolism and may amplify appetite suppression beyond what GLP-1 alone achieves.
- Wegovy HD (semaglutide 7.2 mg) — A pure GLP-1 receptor agonist at a higher dose than standard Wegovy (2.4 mg). It works by slowing gastric emptying, reducing appetite via hypothalamic signaling, and improving insulin dynamics. The 7.2 mg dose delivers more GLP-1 receptor activation, which appears to translate into greater weight loss.
- CagriSema — A fixed-dose combination of amylin + GLP-1. Cagrilintide (amylin analog) acts on brainstem and hypothalamic receptors through a pathway separate from GLP-1, producing additive satiety effects. Semaglutide handles the GLP-1 side. These two hormonal pathways complement each other without overlapping.
In short: Zepbound pairs two incretin hormones, Wegovy HD maximizes a single incretin, and CagriSema combines an incretin with a non-incretin satiety hormone. All three strategies work. The clinical question is which produces the best balance of efficacy, tolerability, and access.
Efficacy: What the Trials Show
Direct comparisons are limited, but the available data tell a clear story:
- CagriSema achieved 22.7% mean weight loss in REDEFINE-1 (vs. placebo, 68 weeks). In the head-to-head REDEFINE-4 trial against tirzepatide, CagriSema reached 23.0% while tirzepatide hit 25.5% — a meaningful gap that favored tirzepatide, though both arms showed strong results.
- Zepbound 15 mg achieved approximately 21% mean weight loss in SURMOUNT-1 (vs. placebo, 72 weeks). The higher dose of tirzepatide used in REDEFINE-4 (maximum dose) produced 25.5%, suggesting dose optimization matters considerably.
- Wegovy HD 7.2 mg achieved approximately 21% mean weight loss in the STEP UP 1 trial (vs. placebo, 68 weeks), a substantial improvement over standard Wegovy's ~15% from earlier STEP trials.
The key takeaway from REDEFINE-4: when CagriSema went head-to-head with tirzepatide, tirzepatide won on the primary endpoint. But both treatments produced clinically transformative weight loss exceeding 20%, and individual responses varied widely within each group.
Side Effects: How They Differ
All three drugs share the familiar GLP-1 gastrointestinal side effect profile: nausea, vomiting, diarrhea, and constipation. The nuances matter, though:
- CagriSema — Nausea (~38%), constipation (~24%), vomiting (~19%). The amylin component adds its own GI slowing effects on top of semaglutide's, which may explain the slightly higher nausea rate. Most symptoms improved after weeks 4–8 of titration.
- Zepbound — Nausea (~26–30%), diarrhea (~21%), constipation (~12%). The GIP component may partially buffer some GI effects. Injection site reactions are uncommon.
- Wegovy HD — Nausea (~30%), diarrhea (~18%), vomiting (~14%). The higher semaglutide dose compared to standard Wegovy means more GI events during titration, but the overall tolerability profile remains manageable for most patients.
Serious adverse events (pancreatitis, gallbladder disease) remain rare across all three drugs and occur at rates comparable to placebo in large trials. No new safety signals have emerged with any of the three.
Can't wait? Oral GLP-1 options available now — from $99/mo
While CagriSema awaits FDA approval, MEDVi offers oral GLP-1 tablets and injectables today. A provider helps you choose the right option.
See GLP-1 Options Available Now →Dosing and Administration
All three are once-weekly subcutaneous injections using auto-injector pens. Titration schedules differ:
- Zepbound — Starts at 2.5 mg, titrates through 5 mg, 7.5 mg, 10 mg, 12.5 mg, to 15 mg over approximately 20 weeks.
- Wegovy HD — Starts at 0.25 mg semaglutide, titrates through the standard Wegovy escalation schedule and continues up to 7.2 mg. Full titration takes approximately 28 weeks.
- CagriSema — Expected to follow a dose-escalation schedule over approximately 16 weeks to the maintenance dose. Exact titration steps will be defined in the approved labeling.
Cost and Availability
| Feature | CagriSema | Zepbound 15 mg | Wegovy HD 7.2 mg |
|---|---|---|---|
| FDA Approval | Pending (~Oct 2026) | Nov 2023 | Mar 2026 |
| Available Now? | No | Yes | Yes |
| Mechanism | Amylin + GLP-1 | GIP + GLP-1 | GLP-1 only |
| Avg Weight Loss | 22.7% | ~21% | ~21% |
| Head-to-Head (REDEFINE-4) | 23.0% | 25.5% | N/A |
| Monthly Self-Pay Cost | Est. $1,000–$1,300 | ~$1,060 | ~$1,350 |
| Insurance Coverage | TBD | Expanding (prior auth typical) | Expanding (prior auth typical) |
| Key GI Side Effects | Nausea 38%, constipation 24% | Nausea 26–30%, diarrhea 21% | Nausea 30%, diarrhea 18% |
The Bottom Line: Don't Wait
CagriSema has genuinely impressive data and will likely become a top-tier option once approved. But it is not approved yet. There is no confirmed PDUFA date, no confirmed price, and no confirmed insurance coverage. Patients who delay treatment to wait for CagriSema are making a bet on regulatory timing at the expense of months of proven therapy.
Zepbound is the strongest available injectable by raw weight-loss numbers and has two-plus years of real-world prescribing data. Wegovy HD 7.2 mg offers comparable efficacy under the Novo Nordisk umbrella for patients who prefer semaglutide or whose insurance covers Wegovy but not Zepbound. Either can be started today.
If CagriSema is approved and proves to be a better fit — whether because of its amylin-based mechanism, tolerability profile, or pricing — switching at that point is straightforward. The worst strategy is doing nothing while waiting for a drug that might not arrive on schedule. Start with what is available, reassess when the landscape changes, and let your prescriber guide the decision.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication.